LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Patrica Young <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Sat, 20 May 2000 23:24:25 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (29 lines)
Came across this blurb on Remicade:
Remicade (infliximab) from Centocor was recently cleared by the FDA for the
treatment of Crohn's disease.

Remicade is the first of a new class of agents that blocks activity of a
key biologic response mediator called tumor necrosis factor alpha (TNF-a).

Scientists believe that Remicade reduces intestinal inflammation in
patients with Crohn's disease by binding to and neutralizing THF-a on the
cell membrane and in the blood and by destroying TNF-a producing cells.
This action  may explain why Remicade is a particularily effective
inhibitor of TNF-a.

In clinical trials, remicade reduced the number of open, draining fistulas,
a painful  complication  of Crohn's disease..................

Approximately 5% of trial subjects discontinued Rermicade treatment.

The most common reasons for discontinuation were infusion reactions to the
treatments and infections.  The most common adverse reactions included
nausea, upper respiratory tract infections and abdominal pain.  Remicade
may also lead to the development of autoantibodies.

             ***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2